Laurel Therapeutics

Laurel Therapeutics is a preclinical-stage biotechnology company focused on developing novel small molecule inhibitors for cancer immunotherapy. The company specifically targets VISTA (V-domain Ig suppressor of T cell activation), a potent immune checkpoint protein that limits T-cell activity within the tumor microenvironment. By inhibiting VISTA, Laurel Therapeutics aims to restore anti-tumor immunity and provide effective treatments for patients with solid tumors, including those resistant to current PD-1/PD-L1 therapies. The company's approach leverages deep expertise in immune checkpoint biology to address unmet needs in the oncology landscape.